Thomas Samuel McClenahan Net Worth

The estimated Net Worth of Thomas Samuel Mc Clenahan is at least $3.68 million dollars as of 2 January 2022. Mr Clenahan owns over 2,000 units of Masimo Corp stock worth over $2,919,952 and over the last 12 years he sold MASI stock worth over $0. In addition, he makes $757,634 as Exec. VP et Gen. Counsel & Corp. Sec. at Masimo Corp.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr McClenahan MASI stock SEC Form 4 insiders trading

Mr has made over 23 trades of the Masimo Corp stock since 2015, according to the Form 4 filled with the SEC. Most recently he exercised 2,000 units of MASI stock worth $228,380 on 2 January 2022.

The largest trade he's ever made was exercising 22,000 units of Masimo Corp stock on 31 August 2015 worth over $465,960. On average, Mr trades about 4,392 units every 63 days since 2013. As of 2 January 2022 he still owns at least 25,571 units of Masimo Corp stock.

You can see the complete history of Mr Clenahan stock trades at the bottom of the page.

Mr. Thomas Samuel McClenahan biography

Thomas Samuel McClenahan is the Exec. VP, Gen. Counsel & Corp. Sec. at Masimo Corp.

What is the salary of Mr McClenahan?

As the Exec. VP et Gen. Counsel & Corp. Sec. of Masimo Corp, the total compensation of Mr McClenahan at Masimo Corp is $757,634. There are 11 executives at Masimo Corp getting paid more, with Joseph Kiani having the highest compensation of $14,996,100.

How old is Mr McClenahan?

Mr McClenahan is 48, he's been the Exec. VP et Gen. Counsel & Corp. Sec. of Masimo Corp since . There are 16 older and 8 younger executives at Masimo Corp. The oldest executive at Masimo Corp is Thomas Harkin, 80, who is the Independent Director.

What's Mr McClenahan's mailing address?

Thomas's mailing address filed with the SEC is C/O MASIMO CORPORATION, 52 DISCOVERY, IRVINE, CA, 92618.

Insiders trading at Masimo Corp

Over the last 17 years, insiders at Masimo Corp have traded over $198,004,099 worth of Masimo Corp stock and bought 212,683 units worth $10,354,127 . The most active insiders traders include Joe E Kiani, Edward L Cahill et Yongsam Lee. On average, Masimo Corp executives and independent directors trade stock every 14 days with the average trade being worth of $2,669,077. The most recent stock trade was executed by Joe E Kiani on 8 August 2024, trading 231,748 units of MASI stock currently worth $8,769,344.

What does Masimo Corp do?

masimo (nasdaq: masi) is a global medical technology company that develops and manufactures innovative noninvasive patient monitoring technologies, including medical devices and a wide array of sensors. our work is making a measurable difference in the world by saving, extending and improving the lives of people of all ages, in all walks of life for more than 27 years, our innovative medical technologies and noninvasive patient monitoring solutions have been solving ‘unsolvable’ problems. the result is a portfolio of clinically-proven products that lead the way in innovation, performance and patient safety by giving health care providers the information they need to optimize clinical decision-making. masimo is for‘what-ifers’, ‘never-say-never-ers’, and ‘world changers’—people who look beyond what others see. we're looking for people who can, do, and will make a difference. we think you'll like what you see.

Complete history of Mr Clenahan stock trades at Masimo Corp

Masimo Corp executives and stock owners

Masimo Corp executives and other stock owners filed with the SEC include:

• Joseph Kiani,
  Chairman of the Board, Chief Executive Officer
• Bilal Muhsin,
  Chief Operating Officer
• Joseph E. Kiani,
  Founder, CEO & Chairman
• Tao Levy,
  Executive Vice President - Business Development
• Anand Sampath,
  Executive Vice President - Operations & Clinical Research
• Tom McClenahan,
  Executive Vice President, General Counsel, Corporate Secretary
• Micah Young,
  Chief Financial Officer, Executive Vice President
• Jon Coleman,
  President - Worldwide Sales, Professional Services and Medical Affairs
• Yongsam Lee,
  Executive Vice President, Chief Information Officer
• Bilal Muhsin,
  Chief Operating Officer
• Micah Young,
  Exec. VP of Fin. & CFO
• Thomas Samuel McClenahan,
  Exec. VP, Gen. Counsel & Corp. Sec.
• Tao Leopold Levy,
  Exec. VP of Bus. Devel.
• Adam Mikkelson,
  Independent Director
• Craig Reynolds,
  Independent Director
• Thomas Harkin,
  Independent Director
• Sanford Fitch,
  Independent Director
• H Michael Cohen,
  Independent Director
• Julie Shimer,
  Independent Director
• Steven Barker,
  Director
• Dr. Steven J. Barker,
  Chairman of Scientific Advisory Board & Chief Science Officer
• Eli Kammerman,
  Investor Relations Officer
• J. Todd Koning,
  Chief Accounting Officer
• Jon Coleman,
  Pres of Worldwide Sales, Professional Services & Medical Affairs
• Yongsam Lee,
  Exec. VP & Chief Information Officer
• Thierry Leclercq,
  Exec. VP of Bus. Devel.
• Anand Sampath,
  Exec. VP of Operations & Clinical Research
• Joe E Kiani,
  CEO and Chairman of the Board
• Raad Mark De,
  EVP & Chief Financial Officer
• Thierry Leclercq,
  EVP, Bus Dev
• Paul Jansen,
  Executive VP, Marketing
• Thomas Samuel Mc Clenahan,
  EVP, GEN COUNSEL & CORP SEC
• Michelle Brennan,
  Director
• Blair Tripodi,
  COO, Consumer Division
• Christopher Kilpatrick,
  EVP, Business Dev., GC & Sec.
• Olivier Berthon,
  President, Masimo Europe
• Michael O'reilly,
  EVP, Medical Affairs
• Ammar Al Ali,
  Chief Technical Officer
• David Goodman,
  EVP, Business Development
• Stephen M Moran,
  EVP, General Counsel
• Stephen E. Paul,
  Vice President, US Acute Care
• Rick Fishel,
  President of Masimo Americas
• Robert Coleman,
  Director
• Brian Campbell,
  
• Mohamed Elmandjra,
  Pres., Worldwide OEM Business
• Edward L Cahill,
  Director
• Jack W Lasersohn,
  Director
• Anthony Allan,
  Chief Operating Officer
• Robert A Chapek,
  Director
• Ramshorst David J Van,
  SVP, Chief Accounting Officer
• Kevin P Duffy,
  President, Consumer
• Capital Management Lp Polit...,
  
• Rolf A Classon,
  Director